Does Medicare Cover Ozempic? GLP-1 Coverage Rules in 2026

GLP-1 receptor agonists like Ozempic have become some of the most prescribed medications in the United States, yet millions of Medicare beneficiaries remain unsure whether their plan will pick up the tab. If you’re asking does Medicare cover Ozempic, the short answer is: it can, but coverage hinges on why it is prescribed and which part of Medicare you carry. The single most important rule to understand is the difference between a diabetes prescription and a weight-loss prescription, because that distinction determines everything. This is a question worth revisiting in 2026 even if you checked a year ago.

Understanding Ozempic and Why It Matters for Medicare

Ozempic (semaglutide) is an injectable GLP-1 receptor agonist manufactured by Novo Nordisk. The FDA originally approved it in 2017 for the treatment of type 2 diabetes, where it helps lower blood sugar and reduce A1C. Its labeled uses have since broadened: Ozempic is also approved to reduce the risk of major cardiovascular events (such as heart attack and stroke) in adults who have type 2 diabetes together with established heart disease, and its label has expanded to include reducing the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease. Ozempic is not FDA-approved for weight management on its own — that indication belongs to its higher-dose sibling, Wegovy, which is the same active drug (semaglutide) sold under a different brand for a different purpose.

For Medicare enrollees, the distinction between diabetes/heart-risk treatment and weight loss is critical, because it is written into federal law. By statute, Medicare Part D is prohibited from covering drugs when they are used for weight loss. That single rule explains most of the confusion around does Medicare cover Ozempic, so it is worth keeping front and center as we walk through the details.

Medicare Part D Coverage for Ozempic in 2026

Medicare Part D is the outpatient prescription drug benefit, and it’s the primary pathway through which beneficiaries access Ozempic. When Ozempic is prescribed for type 2 diabetes — its original FDA-approved indication — most Part D plans include it on their formularies. Because it is also FDA-approved to reduce cardiovascular risk in people who have type 2 diabetes and heart disease, that approved use is likewise a covered medical indication. What varies from plan to plan is the formulary tier Ozempic sits on, which drives your out-of-pocket cost.

Starting in 2025, the Inflation Reduction Act capped annual out-of-pocket prescription drug spending under Part D at $2,000. That cap is indexed each year, and for 2026 it is approximately $2,100, according to Medicare.gov. Once your out-of-pocket spending on covered Part D drugs reaches that ceiling, you pay nothing more for covered drugs for the rest of the calendar year. That is meaningful protection for anyone taking an expensive medication, since Ozempic’s list price runs several hundred dollars a month or more without coverage. (Treat all prices here as estimates that vary by pharmacy, plan, and year — verify current figures directly.)

Keep in mind that Part D plans can require prior authorization or step therapy before approving Ozempic. Your prescriber may need to document that you’ve tried metformin or other first-line diabetes medications before the plan agrees to cover a GLP-1. Check your plan’s formulary at Medicare.gov Plan Compare for the specifics that apply to you.

Does Medicare Cover Ozempic for Weight Loss?

This is the crux of the whole question, and the answer is clear: no, not when it is prescribed for weight loss alone. Medicare Part D is barred by law from covering any drug used for weight loss. Because Ozempic is FDA-approved for type 2 diabetes (and related cardiovascular and kidney indications) rather than for obesity, prescribing it off-label purely for weight management falls outside what Part D can pay for.

It is important to be precise about what has and has not changed. In late 2024, federal officials floated a proposal that would have reinterpreted the statute to let Medicare cover anti-obesity medications, but that proposal was not finalized. As a result, heading through 2026, standard Medicare Part D still does not cover drugs prescribed solely for weight loss. Legislative efforts such as the Treat and Reduce Obesity Act continue to push for change, and a small number of Medicare Advantage plans market supplemental benefits touching on obesity care, but broad, guaranteed Medicare coverage of weight-loss drugs is not the reality in 2026. If you see a claim that Medicare “now covers Ozempic for weight loss,” treat it skeptically and verify against official sources.

If your physician prescribes Ozempic for diabetes and you also happen to lose weight, coverage generally still applies, because the covered indication (diabetes) is the reason for the prescription. The key factor is the diagnosis attached to the claim. A type 2 diabetes diagnosis (ICD-10 code E11.x) typically supports coverage, while an obesity-only diagnosis generally does not. Talk with your doctor’s office so claims are submitted accurately for your actual medical condition — coding for a diagnosis you do not have is never appropriate.

Ozempic vs. Wegovy vs. Zepbound: The Coverage Distinction

Because these drugs are frequently confused, it helps to line them up. Understanding the differences is the fastest way to predict whether Medicare will pay.

• Ozempic (semaglutide): Approved for type 2 diabetes and for reducing cardiovascular risk in diabetics with heart disease. Part D can cover it for those uses — not for weight loss.
• Wegovy (semaglutide): The same active ingredient as Ozempic, at higher doses, branded and approved for chronic weight management. Because Part D cannot cover weight-loss drugs, Wegovy is not covered for obesity alone. However, Wegovy also carries an FDA-approved indication to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults with established heart disease who are overweight or have obesity — and Part D plans can cover Wegovy for that heart-risk-reduction use, not for weight loss by itself.
• Zepbound (tirzepatide): Branded for weight management (and therefore not covered for obesity alone), but also FDA-approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. That OSA indication is a medical use that a Part D plan may cover even though weight loss itself is excluded — a useful illustration of how an approved non-weight-loss indication can open the door to coverage.

The through-line across all three: Medicare follows the FDA-approved medical indication and the diagnosis on the claim, and it excludes weight loss as a standalone reason. Whether the exact brand is covered still depends on your specific plan’s formulary.

Medicare Advantage and GLP-1 Coverage

Medicare Advantage (Part C) plans, offered by private insurers, must cover everything Original Medicare covers, and they can offer extra benefits. Some Medicare Advantage plans have broader GLP-1 formularies or market supplemental wellness benefits, but they operate under the same federal rule: Part D drug coverage cannot pay for a drug used for weight loss alone. So an Advantage plan may make your covered GLP-1 cheaper or easier to obtain for diabetes, but it does not override the statutory weight-loss exclusion.

According to the Centers for Medicare & Medicaid Services (CMS), Medicare Advantage now enrolls more than half of all Medicare beneficiaries, and many of these plans compete on drug benefits. That means your GLP-1 cost-sharing could differ meaningfully between a standalone Part D plan and an Advantage plan — worth comparing when the diagnosis is covered.

During the Annual Election Period (October 15 through December 7), you can compare plans and switch to one that better covers your medications. Use the Medicare.gov plan finder tool to search specifically for your drug’s coverage in your area.

What You’ll Pay Out of Pocket for Ozempic

Even with Medicare coverage, Ozempic isn’t cheap, and exact prices vary widely by plan, pharmacy, and year — so the figures below are rough estimates to verify, not quotes. Without insurance, a single monthly pen commonly runs several hundred dollars or more at the pharmacy. With Part D coverage, your cost depends on the plan’s tier structure:

• Preferred brand tier: Copays are often in the low-to-mid double digits per month, depending on the plan.
• Non-preferred brand tier: Copays or coinsurance are typically higher, sometimes over $100 per month.
• Specialty tier: Some plans apply coinsurance (a percentage of the drug’s cost) rather than a flat copay, until you reach the annual out-of-pocket cap.

Thanks to the roughly $2,100 annual out-of-pocket cap for 2026 under the Inflation Reduction Act, even beneficiaries on expensive specialty-tier drugs will see their total yearly spending on covered drugs limited. Additionally, the Medicare Prescription Payment Plan lets you spread your out-of-pocket costs across monthly installments rather than paying large amounts at the pharmacy counter at once. Learn more about how drug pricing works in our healthcare policy guide.

Prior Authorization and Step Therapy Requirements

Most Medicare Part D plans require prior authorization before they’ll approve Ozempic. This means your doctor must submit documentation showing the medication is medically necessary for your condition. Common requirements include:

• A confirmed diagnosis of type 2 diabetes (or another covered indication)
• Documentation of A1C levels
• Evidence that you’ve tried and failed, or cannot tolerate, first-line treatments like metformin
• Sometimes, evidence that other GLP-1 options were considered

Step therapy — where the plan requires you to try lower-cost alternatives first — is common with GLP-1 medications. If your prior authorization is denied, you have the right to appeal. The Medicare Part D appeals process allows you to request an expedited review, especially if your doctor believes a delay could harm your health.

Alternatives to Ozempic Covered by Medicare

If your plan doesn’t cover Ozempic or places it on an unfavorable tier, other GLP-1 medications approved for type 2 diabetes may be available at a lower cost. Trulicity (dulaglutide), Victoza (liraglutide), and Rybelsus (oral semaglutide) are all FDA-approved for type 2 diabetes and covered by many Part D plans. Your doctor can help determine which medication best suits your clinical needs while keeping costs manageable.

Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, is another option. It is FDA-approved for type 2 diabetes, and some Part D plans cover it at a similar or lower tier than Ozempic. Note that Mounjaro (diabetes) and Zepbound (weight management and obstructive sleep apnea) are the same drug under different brands — the same diabetes-versus-weight-loss coverage logic applies. You can review common effects in our guide to Mounjaro side effects.

How to Save on Ozempic With Medicare

Beyond choosing the right plan, several strategies can reduce your Ozempic costs. Novo Nordisk offers patient assistance for eligible individuals, though Medicare beneficiaries generally cannot use manufacturer copay cards due to federal anti-kickback rules. State pharmaceutical assistance programs (SPAPs) and the Medicare Extra Help/Low-Income Subsidy program can substantially lower costs for qualifying enrollees.

If you have limited income and resources, the Extra Help program through Social Security can reduce Part D premiums, deductibles, and copayments to modest amounts for those who qualify. Additionally, exploring Ozempic pricing options across pharmacies with cash-price tools can sometimes reveal lower prices if a coverage gap exists — though cash payments typically do not count toward your Part D out-of-pocket total.

Frequently Asked Questions

Does Medicare cover Ozempic for prediabetes?

Generally, no. Medicare Part D covers Ozempic for its FDA-approved indications, and prediabetes is not one of them. Most plans will deny coverage for a prediabetes diagnosis. Your doctor may recommend lifestyle changes or discuss other options.

Can I get Ozempic through Medicare Part B instead of Part D?

Almost always no. Part B covers drugs administered in a clinical setting, not self-administered injectables you use at home. Because Ozempic is self-injected, it falls under Part D in essentially all cases.

What happens if my Medicare plan denies Ozempic coverage?

You can file an appeal through the Part D appeals process. Start by asking your doctor to submit a coverage determination request with supporting medical documentation. If it is denied, you can escalate through multiple levels, including review by an independent entity. Many initial denials are overturned on appeal.

Will Medicare cover Wegovy or Ozempic for weight loss in 2026?

Not for weight loss alone. Federal law bars Part D from covering drugs used for weight loss, and the 2024 proposal to change that was not finalized. Part D can cover Wegovy for its approved cardiovascular-risk-reduction indication in eligible patients with heart disease, and it can cover Ozempic for diabetes or heart-risk reduction — but obesity by itself is not a covered reason. Check your specific plan during open enrollment.

Does Medicare ever cover a GLP-1 for a reason other than diabetes or weight loss?

Yes. Coverage follows the FDA-approved medical indication. For example, Zepbound (tirzepatide) is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and a Part D plan may cover it for that condition even though weight loss itself is excluded. The diagnosis on the claim is what matters.

Bottom Line on Medicare and Ozempic Coverage

Whether does Medicare cover Ozempic for your situation comes down to your diagnosis, your specific plan, and how your claim is coded. For type 2 diabetes — and for reducing cardiovascular risk in diabetics with heart disease — most Part D plans provide coverage, though tier placement and prior authorization vary. For weight loss alone, Part D cannot pay, because federal law excludes weight-loss drugs; the same logic distinguishes Wegovy (covered only for its heart-risk indication, not obesity) from Ozempic. The roughly $2,100 annual out-of-pocket cap for 2026 offers meaningful financial protection once you reach it. Review your plan’s formulary annually, use the appeals process if needed, and explore assistance programs to keep your costs as low as possible. This article is general information, not medical or insurance advice — confirm details with your plan and your clinician.

Sources

• Medicare.gov — Drug coverage (Part D) and costs
• Medicare.gov — Plan Compare
• Centers for Medicare & Medicaid Services (CMS)
• U.S. Food & Drug Administration (FDA) — drug approvals and labels
• Social Security Administration — Medicare Part D Extra Help
• KFF — Medicare drug benefit resources